Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
44 hedge funds and large institutions have $19.6M invested in Viracta Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 13 closing their positions.
370% more call options, than puts
Call options by funds: $47K | Put options by funds: $10K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
10% less funds holding
Funds holding: 49 → 44 (-5)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
38% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 13
54% less capital invested
Capital invested by funds: $42.5M → $19.6M (-$22.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Caxton Corporation
Princeton,
New Jersey
|
+$1.33M |
| 2 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$1.11M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$510K |
| 4 |
BlackRock
New York
|
+$186K |
| 5 |
Two Sigma Investments
New York
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.16M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$816K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$663K |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$288K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$1K | -44 | Closed |
|
|
PA
52
Parallel Advisors
San Francisco,
California
| – | -$17 | -1 | -10% |
|
VIRX Hedge Fund Activity: Q4 2019 in Review
44 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2019, worth a combined $19.6M — down 54% from $42.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of VIRX and 8 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Caxton Corporation, adding an estimated $1.33M. The largest seller was RTW Investments, exiting entirely with an estimated $5M sold.
- 44 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2019, down from 49 in Q3 2019.
- Funds reported $19.6M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2019, down 54% quarter-over-quarter.
- 8 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2019 and 13 closed out, a net change of -5 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2019 was Caxton Corporation, an estimated $1.33M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2019 was RTW Investments, an estimated $5M sold.
Based on aggregated 13F filings for Q4 2019.